ASXL2 (Gene)

Organism:

Homo sapiens

Synonyms:ASXH2, ASXL transcriptional regulator 2, ASXL2, ENTREZ:55252, HGNC:23805, MIM:612991, NM_001369346, NM_001369347, NM_018263, NP_001356275, NP_001356276, NP_060733, SHAPNS

Omim:OMIM:612991

Id:ENSG00000143970

Hgnc:HGNC:23805

Entrez:55252

Ensembl:ENSG00000143970

Description:ASXL transcriptional regulator 2

This gene encodes a member of a family of epigenetic regulators that bind various histone-modifying enzymes and are involved in the assembly of transcription factors at specific genomic loci. Naturally occurring mutations in this gene are associated with cancer in several tissue types (breast, bladder, pancreas, ovary, prostate, and blood). This gene plays an important role in neurodevelopment, cardiac function, adipogenesis, and osteoclastogenesis. [provided by RefSeq, Feb 2017]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ASXL2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ASXL2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ASXL2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ASXL2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ASXL2.

Results found

Linked to

	Label	Description
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 4 V 3 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE162892 ISOX 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE130401 4 V 3 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.